Sutro Biopharma, Inc.Sutro Biopharma, Inc.Sutro Biopharma, Inc.

Sutro Biopharma, Inc.

No trades
See on Supercharts
Market capitalization
‪318.45 M‬USD
−1.79USD
‪−106.79 M‬USD
‪153.73 M‬USD
‪73.79 M‬
Beta (1Y)
2.17

About Sutro Biopharma, Inc.

CEO
William J. Newell
Headquarters
South San Francisco
Employees (FY)
302
Founded
2003
ISIN
US8693671021
FIGI
BBG000R4V3P3
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of STRO is 3.94 USD — it has decreased by 4.83% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sutro Biopharma, Inc. stocks are traded under the ticker STRO.
Sutro Biopharma, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Sutro Biopharma, Inc. has a max estimate of 20.00 USD and a min estimate of 8.00 USD.
STRO earnings for the last quarter are −0.81 USD whereas the estimation was −0.74 USD which accounts for −10.05% surprise. Estimated earnings for the next quarter are −0.27 USD. See more details about Sutro Biopharma, Inc. earnings.
Sutro Biopharma, Inc. revenue for the last quarter amounts to ‪16.92 M‬ USD despite the estimated figure of ‪13.01 M‬ USD. In the next quarter revenue is expected to reach ‪57.36 M‬ USD.
Yes, you can track Sutro Biopharma, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, STRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sutro Biopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
STRO reached its all-time high on Feb 8, 2021 with the price of 28.30 USD, and its all-time low was 2.01 USD and was reached on Nov 13, 2023.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 302.00 employees. See our rating of the largest employees — is Sutro Biopharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sutro Biopharma, Inc. EBITDA is ‪−81.16 M‬ USD, and current EBITDA margin is −53.64%. See more stats in Sutro Biopharma, Inc. financial statements.